menu
    • menu
    [{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Cannabis derivatives","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"VIDO-InterVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Plant based vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ ZYUS Life Sciences ","highestDevelopmentStatusID":"1","companyTruncated":"ZYUS Life Sciences \/ ZYUS Life Sciences "},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Plant-based COVID-19 antigen","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Trichomylin","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Aureuspharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Trichomylin","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"ZYUS Life Sciences \/ Aureuspharma","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Aureuspharma"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"CB receptor","graph1":"Neurology","graph2":"Approved","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Trichomylin","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ivabradine Hydrochloride","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Technology","graph2":"Approved","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by ZYUS Life Sciences

    Menu

    ZYUS Life Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Cannabichromene,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ZYUS Life Sciences Receives NOC from Health Canada for Proof-of-Concept Trial

                            Details : Trichomylin softgels, a first-in-class drug product candidate formulated with a proprietary fixed-dose cannabinoid combination, has been specifically designed for the management of chronic pain.

                            Brand Name : Trichomylin

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 30, 2024

                            Lead Product(s) : Cannabidiol,Cannabichromene,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zydus Lifesciences gets USFDA Nod for Generic Cancer Treatment Capsules

                            Details : Cyclophosphamide-Generic is a DNA cross-linker, small molecule, cytotoxic drug candidate, which is currently being evaluated for the treatment of lymphoma.

                            Brand Name : Cyclophosphamide-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 14, 2023

                            Lead Product(s) : Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zydus Lifesciences Gets USFDA Nod for Generic Heart Failure Treatment Drug

                            Details : USFDA approved generic version of Ivabradine, is a small molecule oral blocker of HCN channels, which is indicated to reduce the risk of hospitalisation for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with cer...

                            Brand Name : Ivabradine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 01, 2023

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Cannabichromene,Tetrahydrocannabinol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels

                            Details : Trichomylin softgels, a first-in-class drug product candidate formulated with a proprietary fixed-dose cannabinoid combination, has been specifically designed for the management of chronic pain.

                            Brand Name : Trichomylin

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 21, 2023

                            Lead Product(s) : Cannabidiol,Cannabichromene,Tetrahydrocannabinol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trichomylin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ZYUS Announces Database Lock for its Phase 1 First-in-Human Clinical Trial

                            Details : Trichomylin® softgels, is a proprietary novel fixed-dose cannabinoid formulation developed by ZYUS to alleviate chronic pain and has the potential to be a safe and effective alternative to opioids – without the devasting addictive qualities

                            Brand Name : Trichomylin

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 15, 2022

                            Lead Product(s) : Trichomylin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabinoid

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ZYUS Life Sciences Launches New Medical Cannabinoid Formulation for Direct to Patient Sales in Canada

                            Details : A new THC-dominant medical cannabinoid formulation, Zylem™ 20:1, for direct sales and distribution to registered medical patients across Canada as a standard of care and expand the potential of protein-based formulations in pursuit of a transformationa...

                            Brand Name : Zylem

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 17, 2021

                            Lead Product(s) : Cannabinoid

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trichomylin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Aureuspharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ZYUS Life Sciences Partners with Portugal’s Aureuspharma to Further Increase International Patient Access to...

                            Details : Under the agreement, ZYUS’ cannabinoid formulations are expected to hit the Portuguese market as early as the second half of 2021. It's lead drug product candidate, Trichomylin® for pain management in a limited number of patients with osteoarthritis.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 27, 2021

                            Lead Product(s) : Trichomylin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Aureuspharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trichomylin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ZYUS Launches HOPE (Human Osteoarthritis Pain Evaluation) Phase 1 First in Human Clinical Trials

                            Details : ZYUS Life Sciences will be launching a first-in-human (FIH) clinical trial on the safety, tolerability and efficacy of its lead drug product candidate, Trichomylin®, through its wholly owned subsidiary, ZYUS Life Sciences Australia Pty. Ltd.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 19, 2021

                            Lead Product(s) : Trichomylin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plant-based COVID-19 antigen

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production

                            Details : Preliminary research results from ZYUS Life Sciences show that plant-based antigens are reactive to anti-COVID-19 antibodies and potentially offer immunity from COVID-19.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 15, 2020

                            Lead Product(s) : Plant-based COVID-19 antigen

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ZYUS Life Sciences

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plant based vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : VIDO-InterVac

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ZYUS Collaborates with USask’s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19

                            Details : ZYUS will leverage its bio-pharmaceutical plant technology platform and expertise to develop and express a protein that VIDO-InterVac has identified as a potential antigen for a COVID-19 vaccine.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 07, 2020

                            Lead Product(s) : Plant based vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : VIDO-InterVac

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth